Head-to-head · WeighScore
Care Bare Rx vs Fierce Health
The verdict
Care Bare Rx takes it — 75/100 to 56.6/100.
Care Bare Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Oral as well as injectable routes for both molecules plus a brand Ozempic lane, bundled with hair, TRT and sexual health.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Care Bare Rx | Fierce Health |
|---|---|---|
| WeighScore | 75/100 | 56.6/100 |
| Grade | C | C |
| Scorecard rank | #43 | #410 |
| Semaglutide | From $199/mo (shared weight-loss price) | $297/mo (3-month plan, compounded) |
| Tirzepatide | From $199/mo (shared weight-loss price) | $497/mo (3-month plan, compounded) |
| Coverage | Multi-state | 30 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #43 · C
Strengths
- Oral tirzepatide as well as injectable — rare on this board
- Brand Ozempic (from $705/mo) and oral Rybelsus beside the compounded line
- LegitScript certified and HIPAA compliant
- One platform if you also want hair, TRT, sexual health or NAD+
Where it loses points
- The advertised "from $199/mo" is one figure shared across all weight-loss treatments — neither molecule priced separately
- Per-dose pricing is quiz-gated, so a titrated cost cannot be modelled beforehand
- No named clinicians, founding year or parent company disclosed
- Compounded medication is not FDA-approved the way brand Ozempic, Wegovy, or Zepbound are
Graded #410 · C
Strengths
- 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer on every product page
- Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
- Microdose tier at $197/mo is one of the lower entry points we've seen
Where it loses points
- No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
- Operating LLC name not disclosed anywhere on the site
- Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
- Clinical provider network not named
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.